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Abstract
Background Some drug safety issues communicated through direct healthcare professional communications (DHPCs) receive 
substantial media coverage, while others do not.
Objectives The objective of this study was to assess the extent of coverage of drug safety issues that have been communicated 
through DHPCs in newspapers and social media. A secondary aim was to explore which determinants may be associated 
with media coverage.
Methods Newspaper articles covering drug safety issues communicated through 387 DHPCs published between 2001 and 
2015 were retrieved from LexisNexis Academic™. Social media postings were retrieved from Coosto™ for drugs included 
in 220 DHPCs published between 2010 and 2015. Coverage of DHPCs by newspapers and social media was assessed during 
the 2-month and 14-day time periods following issuance of the DHPC, respectively. Multivariate logistic regression was 
used to assess potential DHPC- and drug-related determinants of media coverage.
Results 41 (10.6%) DHPC safety issues were covered in newspaper articles. Newspaper coverage was associated with drugs 
without a specialist indication [adjusted odds ratio 5.32; 95% confidence interval (2.64–10.73)]. Negative associations were 
seen for time since market approval [3–5 years 0.30; (0.11–0.82), 6–11 years 0.18; (0.06–0.58)] and year of the DHPC [0.88; 
(0.81–0.96)]. In the social media, 180 (81.8%) drugs mentioned in 220 DHPCs were covered. Social media coverage was 
associated with drugs without a specialist indication [6.92; (1.56–30.64)], and for DHPCs communicating clinical safety 
issues [5.46; (2.03–14.66)].
Conclusions Newspapers covered a small proportion of DHPC safety issues only. Most drugs mentioned in DHPCs were 
covered in social media. Coverage in both media were higher for drugs without a specialist indication.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-020-00922 -7) contains 
supplementary material, which is available to authorized users.
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Key Points 
Safety issues described in direct healthcare professional 
communications (DHPCs) received only limited cover-
age by newspapers. The drugs concerned were frequently 
referred to in social media
Coverage of DHPCs by newspapers was declining during 
the 15-year study period, with older drugs and drugs that 
did not require a specialist indication being covered more 
frequently
Social media coverage was associated with drugs not 
requiring a specialist prescriber and for DHPCs commu-
nicating about clinical safety issues
 E. de Vries et al.
1 Introduction
Regulators and industry routinely monitor the safety of 
medicines after their approval. Once an important safety 
signal is identified and confirmed, healthcare professionals 
are informed about the new drug safety issue [1–3]. In the 
European Union, the direct healthcare professional commu-
nication (DHPC, also known as the “Dear Doctor Letter”) is 
the most commonly used safety communication tool. In the 
past decades, its use has increased to around 30 letters annu-
ally [4, 5]. European Union pharmacovigilance legislation, 
enforced in 2012, requires that the impact of a regulatory 
safety communication is routinely monitored [3, 6–8]. The 
authors of three systematic reviews of these impact evalu-
ations concluded, however, that it is difficult to disentangle 
the effect of regulatory safety communications from the 
effect of concomitant media attention [5, 9, 10].
Some drug safety issues received excessive media atten-
tion. An example is suicidality in adolescents using selective 
serotonin reuptake inhibitors [11, 12]. In consequence, this 
media attention may affect how the safety issue is perceived 
by both healthcare professionals and patients, and may 
amplify the response to regulatory safety communications. 
An intended decrease in selective serotonin reuptake inhibi-
tor use in children and adolescents was observed in the Neth-
erlands coinciding with a period of extensive media coverage 
[11]. However, this media attention may also have contrib-
uted to an observed unintended decrease of use in adults 
[11]. While large changes in drug use have been reported 
for safety issues that were extensively covered by the media 
[13–18], systematic reviews suggested a more modest, if any, 
effect for a wide range of studied safety communications 
that generally may not have received much media attention 
[5, 9, 10]. It remains, however, largely unknown to what 
extent media in general pay attention to drug safety issues 
reviewed by regulatory authorities. It seems that extensive 
newspaper coverage of safety issues particularly concerned 
drugs with large numbers of users, e.g. cyproterone acetate/
ethinylestradiol (Diane-35) and rofecoxib (Vioxx). Again, 
not much is known about the association of characteristics 
of the safety issue communicated through DHPCs and media 
coverage. Moreover, media attention may already occur 
before a safety issue is officially communicated through a 
DHPC. For instance, following publication of a safety issue 
in a scientific journal [19].
Most research regarding media attention for drug safety 
issues has focussed on traditional media, such as newspapers 
[11, 12, 18, 20–24]. As social media use is increasing over 
time and the public is becoming more and more empowered, 
it is likely that safety issues will also be mentioned on social 
media. It is not only used as a meeting place for patients 
seeking support, but also by people with similar views on the 
use of certain types of drugs, like ‘vaccine refusers’ [25–28], 
and for professionals as well to be in contact with colleagues 
[29]. A survey study showed that almost half of the respond-
ers used social media for advice about acne treatment with 
only a third of them making treatment changes in line with 
clinical guidelines [30]. In addition, some work has been 
performed to mine possible adverse drug reactions from 
social media postings, albeit with mixed results [31, 32]. 
One could expect, however, that safety issues for some drug 
types or drug classes will receive more media coverage than 
others but as yet this subject has not been studied.
The present study aims to provide a quantitative over-
view of the newspaper and social media coverage of drug 
safety issues that have been communicated through DHPCs. 
Secondary aims are to identify determinants that may be 
associated with media coverage, and to explore what extent 
media uptake was seen before and/or after the publication 
of a DHPC.
2  Methods
2.1  Study Design
In this cohort study, we assessed whether drug safety issues 
addressed in DHPCs in the Netherlands were covered by 
newspapers and social media. Direct healthcare professional 
communications published between 1 January, 2001 and 1 
January, 2016 were included in this study. The index date 
was defined as the date the DHPC was published on the 
Dutch Medicines Evaluation Board website; www.cbg-meb.
nl. This is the same date the healthcare professionals receive 
the DHPC as a paper-based letter. Direct healthcare profes-
sional communications concerning recalls were included 
when published with supervision of the Medicines Evalu-
ation Board. Media coverage was assessed in the period 
around the DHPC publication because media may already 
report on an issue while the regulators are still investigating 
a safety signal and/or have not yet published the DHPC.
2.2  Outcome Measures
2.2.1  Primary Aim Newspapers
Newspaper coverage was measured as any coverage of the 
drug safety issue (yes/no) in the 2 months after the DHPC 
was published (primary outcome).
2.2.2  Secondary Aim Newspapers
For the secondary aim, we assessed: (1) any newspaper 
coverage of the safety issue in the 2 months before the 
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publishing of the DHPC; (2) the number of newspaper 
articles specifically reporting on the safety issue communi-
cated through the DHPC in the 2 months before and in the 
2 months after the DHPC was published; and (3) the number 
of issues covered at least 20 times in the 2 months before or 
in the 2 months after the DHPC was published.
2.2.3  Primary Aim Social Media
Social media coverage was defined as any coverage of the 
drug (yes/no) in the 14 days after the DHPC was published 
(primary outcome).
2.2.4  Secondary Aim Social Media
For the secondary aim, we assessed: (1) any coverage of the 
drug categorised in the 14 days before the publishing of a 
DHPC; (2) the number of social media postings about the 
drug for which a DHPC was published in the 14 days before 
and in the 14 days after its issuing; and (3) the number of 
drugs with at least 100 postings in the 14 days before or in 
the 14 days after the DHPC was published.
2.3  Media Data Sources
2.3.1  Newspapers
Newspaper articles were retrieved from LexisNexis Aca-
demic™, a database containing printed newspaper and 
magazine articles. We searched for articles mentioning the 
drug name, Dutch and English spelling of the International 
Nonproprietary Name and/or brand name, as used in DHPCs 
published between 1 January, 2001 and 1 January, 2016. All 
articles were read by two researchers, who independently 
identified those articles that reported on the safety issue. In 
the case of disagreement, a third researcher was consulted.
2.3.2  Social Media
Web postings were retrieved from Coosto™, a dynamic 
online repository for social media that contains publicly 
available messages from platforms such as Facebook and 
Twitter, but also fora and reactions on news websites. All 
postings of currently available public accounts are included 
in this repository. When an account removes a posting or 
changes from public to private, the posting is no longer 
included in the repository. The repository of social media 
could only be searched from 2009 onwards. We limited 
the search to DHPCs published between 1 January, 2010 
and 1 January, 2016. Web postings were retrieved using 
the drug International Nonproprietary Name and/or brand 
names within one search. In case the drug International 
Nonproprietary Name or brand name ended with -ine or -in, 
both options were used as this was a common misspelling 
because of differences in the spelling of Dutch and English 
drug names. Postings in other than the Dutch language were 
excluded. Given the large volume of relatively short mes-
sages, we were not able to reliably identify postings report-
ing on the safety issue involved. We, therefore, included 
all postings retrieved regardless of their content. The time 
period in which web postings were retrieved around the 
DHPC was shorter than for newspaper articles. We antici-
pated that if the DHPC would trigger a response, this would 
be relatively quick after the DHPC and was more likely to 
concern the safety issue. In addition, we retrieved postings 
in two reference periods for comparison: (1) a 28-day period 
preceding the time period around the DHPC and (2) a 28-day 
period 1 year later corresponding with the time around the 
DHPC, for a sensitivity analysis.
2.4  Determinants
We identified several drug and DHPC characteristics as 
potential determinants, based on previous research that 
examined factors associated with the impact of DHPCs 
[33]. These included drug class, type of molecule, orphan 
drug status, drug use, specialist indication, drug age, year 
and month in which the DHPC was published, type of issue 
communicated through the DHPC, and whether the DHPC 
concerned market withdrawal or suspension of the drug.
The following definitions and categorisations were 
used: drug class defined at the first level of the Anatomi-
cal Therapeutic Chemical (ATC) code; type of molecule 
categorised as biological, small molecule or vaccine; 
orphan drug status categorised as yes or no; drug use at 
the time the DHPC was published categorised as low (1 
to < 1000 users), moderate (1000–10,000 users), widely 
used (> 10,000 users) or unknown based on data retrieved 
from The Drug Information System of the National Health 
Care Institute (GIP database that contains data on nation-
wide reimbursed drugs dispensed by public pharmacists; 
the category unknown covers drugs dispensed over the 
counter as well as drugs used in the hospital setting 
only); specialist indication, defined as a medication that 
according to the Summary of Product Characteristics or 
national guidelines recommendation should (initially) be 
prescribed by a specialist (yes/no); drug age, defined as 
the time between registration (marketing authorisation) 
and the publishing of the DHPC categorised as ≤ 2 years, 
3–5 years, 6–11 years and > 11 years; the year the DHPC 
was published;  type of issue communicated through the 
DHPC categorised as a new clinical issue or not, a drug 
shortage and/or a defect/manufacturing problem (more 
than one type of issue per DHPC possible) as yes or no; 
and drug withdrawal or suspension categorised as yes or 
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no. Direct healthcare professional communication and 
drug characteristics were independently classified by 
two researchers, and in the case of disagreement, a third 
researcher was consulted.
2.5  Analyses
Descriptive statistics were used to report whether, how 
often, and when newspapers and social media covered 
DHPC-related drug safety issues respectively in the study 
period. As the data were paired, a McNemar test was per-
formed to analyse coverage before and after the DHPC 
was published.
Univariate and multivariate logistic regression analyses 
were used to explore which drug or DHPC characteris-
tics were associated with any newspaper coverage in the 
2 months after the DHPC was published, and any social 
media postings in the 14 days after the publishing of the 
DHPC. Potential determinants with a p value of less than 
0.20 in univariate analyses were entered in the full multi-
variate regression model. In addition, specialist indication 
and drug use were entered in the model separately and 
with an interaction term as it was expected that special-
ist indication had a more limited use. Subsequently, we 
performed a backward elimination regression removing 
determinants with the highest p value until in the final 
model only, the most likely relevant determinants with a 
p ≤ 0.05 remained.
A sensitivity analysis was performed for social media 
coverage, in which the average 14-days coverage in the two 
above-defined reference periods was subtracted from the 
coverage in the 14 days after the publishing of the DHPC. 
When the DHPC involved a withdrawal or suspension, only 
the first reference period was used.
All analyses were performed using SPSS Statistics 23 
(IBM SPSS Inc., Chicago, IL, USA).
3  Results
Between 1 January, 2001 and 1 January, 2016, 387 DHPCs 
were published concerning 250 different drugs, of which 
220 DHPCs for 164 drugs were published between 1 Janu-
ary, 2010 and 1 January, 2016 (Fig. 1a,b). The number of 
DHPCs published per year ranged from 12 in 2002 to 48 
in 2011 (Fig. 1). A considerable number of DHPCs was 
published for antineoplastic and immunomodulating agents 
(ATC code L: 27.4%). The majority of the drugs involved 
(76.2%) had a specialist indication (Table 1). Most DHPCs 
concerned a clinical issue (94.6%), occasionally in combina-
tion with a delivery issue or defect/recall. Only 22 (5.7%) 
DHPCs announced a drug withdrawal, of which 18 had a 
safety issue as an underlying reason.
3.1  Newspapers
In total, 457 newspaper articles reported on the drug safety 
issue in the 2 months after the DHPC was published (pri-
mary outcome), covering 41 (10.6%) of the 387 DHPCs 
published in the 15-year study period. The median number 
of articles per covered DHPC was two [interquartile range 
(IQR) 1.0; 11.5]. The years with the highest percentages of 
newspaper coverage were 2001 (43.8% of DHPCs), 2004 
(25.0%) and 2008 (18.5%) (Fig. 1a). Direct healthcare pro-
fessional communications for drugs of the ATC classes car-
diovascular system (C), alimentary tract and metabolism 
(A) or nervous system (N) had the highest coverage (20.8%, 
20.0% and 17.7%, respectively). Widely used drugs (24.7%), 
drugs without a specialist indication (26.1%) and older drugs 
were covered most frequently (18.5%) (Table 1). In the mul-
tivariate analysis, the following determinants were included; 
ATC code, orphan drug, drug use, drug, specialist indica-
tion, drug age, DHPC year and drug use*specialist indica-
tion. The multivariate analysis showed that safety issues for 
drugs without a specialist indication were more likely to be 
covered than safety issues for drugs with a specialist indi-
cation [adjusted odds ratio (ORadj) 5.32; 95% confidence 
interval (2.64–0.73)] (Table 1). Drugs approved between 
3–5 years and 6–11 years were less likely to be covered than 
drugs with a marketing authorisation older than 11 years 
[respectively, 0.30; (0.11–0.82) and 0.18; (0.06–0.58)], 
while drugs approved ≤ 2 years were not differently covered 
[0.45; (0.19–1.10)]. In addition, coverage by newspaper 
decreased over time [0.88; (0.81–0.96)]. Remaining drug 
and DHPC characteristics were less likely to be associated 
with newspaper coverage (Table 1).
3.1.1  Secondary Aim
In the 2 months before DHPCs were published, 326 news-
paper articles had already reported on the drug safety issues 
communicated through these DHPCs. These articles cov-
ered 28 (7.2%) of the 387 DHPCs published in the 15-year 
study period. The median number of postings per covered 
DHPC was 3.5 (IQR 1; 19.75). Overall, only 55 (14.2%) of 
the DHPCs were covered both in the 2 months before and/
or after the DHPC was published. Drug safety issues were 
numerically more often covered after (7.0%) than before 
(3.6%) a DHPC had been published (McNemar’s nominal 
p = 0.06).
In the 2 months after the DHPC was published, news-
paper articles covered seven safety issues 20 times or 
more; i.e. cerivastatin (two cases: 76 articles after the 
Media coverage of DHPCs
DHPC on concomitant use with gemfibrozil contrain-
dicated, due to risk of rhabdomyolysis and 95 after the 
DHPC on temporary discontinuation of cerivastatin), 
moxifloxacin (38 articles after the DHPC on severe skin 
and liver reactions) and doxorubicin (two cases: 34 arti-
cles after both DHPCs on shortage) [Fig. 2, Table 1 of the 
Electronic Supplementary Material (ESM)]. Two of these 
DHPCs were also covered more than 20 times before the 
DHPC was published: celecoxib (26 articles after and 
55 before the DHPC on increased cardiovascular risk) 
and cyproterone acetate/ethinylestradiol (25 articles after 
and 43 before the DHPC on restriction of indication, new 
contra-indication due to venous thromboembolism and 
arterial thromboembolism risk). In the 2 months before 
the DHPC was published, five safety issues were cov-
ered more than 20 times. These publications concerned 
rimonabant (two cases: 49 articles before the DHPC on 
risk of depression and 20 before the DHPC on suspen-
sion registration due to severe psychiatric risk), strontium 
ranelate [24 articles before the DHPC on drug reaction 
with eosinophilia and systemic symptoms (DRESS)], 
diclofenac (24 articles before the DHPC on new contra-
indication due to cardiovascular risk) and cabazitaxel (23 
articles before the DHPC on dosing errors due to prepara-
tion errors) (Fig. 2, Table 1 of the ESM).
3.2  Social Media
A total of 5928 social media postings were retrieved men-
tioning the name of a drug for which a DHPC was pub-
lished between 1 January, 2010 and 1 January, 2016. Of the 
220 DHPCs published, 180 (81.8%) were covered by social 
media in the 14 days after the DHPC was published (pri-
mary outcome). The median number of postings per covered 
DHPC was eight (IQR 3.25; 19). Highest coverage was seen 
for moderately (1000–10,000) and widely used (> 10,000) 
drugs, and for drugs without a specialist indication (89.5%, 
92.3% and 95.8%, respectively). Drugs for which a DHPC 
was published because of a defect, shortage or withdrawal 
received lower coverage than clinical issues [70.2%, 66.7% 
and 66.7% vs 84.9%, respectively (Table 2)]. In the multi-
variate analysis, the following determinants were included: 
Fig. 1  a Newspaper coverage. 
This figure shows the number 
of direct healthcare professional 
communications (DHPCs) 
published from 1 January, 2001 
up to 1 January, 2016. Green 
bars indicate that drug safety 
issues addressed in DHPCs 
were covered in newspaper arti-
cles, dark orange bars indicate 
no coverage. b Social media 
coverage. This figure shows the 
number of DHPCs published 
between 1 January, 2010 and 
1 January, 2016. Light orange 
bars indicate that the names of 
drugs for which DHPCs were 
published were covered in 
social media, dark orange bars 
indicate no coverage. Program 
used: Rstudio
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Table 1  Determinants of newspaper coverage in the 2 months after the publishing of a direct healthcare professional communication (DHPC): 
univariate, full multivariate and final multivariate analyses
DHPCs (%) Covered (%) Univariate p value Full multivariate 
model
p value Final multivariate 
model
p value
387 41 (10.6) OR (95% CI) ORadj (95% CI) ORadj (95% CI)
Drug class (ATC 
code)
0.077 0.794
 A 45 (11.6) 9 (20.0) Ref Ref
 B 35 (9.0) 3 (8.6) 0.38 (0.09–1.51) 0.62 (0.13–3.02)
 C 24 (6.2) 5 (20.8) 1.05 (0.31–3.59) 1.14 (0.25–5.31)
 J 43 (11.1) 3 (7.0) 0.30 (0.08–1.20) 0.62 (0.13–2.87)
 L 106 (27.4) 5 (4.7) 0.20 (0.06–0.63) 0.66 (0.16–2.73)
 M 35 (9.0) 3 (8.6) 0.38 (0.09–1.51) 0.37 (0.08–1.81)
 N 45 (11.6) 8 (17.7) 0.87 (0.30–2.49) 0.81 (0.24–2.77)
 Other 54 (14.0) 5 (9.3) 0.41 (0.13–1.32) 0.36 (0.09–1.44)
Type of molecule 0.765
 Biological 103 (26.6) 9 (8.7) Ref
 Small molecule 282 (72.9) 32 (11.3) 1.34 (0.62–2.91)
 Vaccine 2 (0.5) 0 (0.0) 0.00 (–)
Orphan drug 0.086 0.660
 No 342 (88.4) 40 (11.7) Ref Ref
 Yes 45 (11.6) 1 (2.2) 0.17 (0.02–1.28) 0.62 (0.07–5.35)
Drug use 0.001 0.246
 Low (1 to < 1000) 111 (28.7) 9 (8.1) Ref Ref
 Moderate (1000–
10,000)
80 (20.7) 6 (7.5) 0.92 (0.31–2.69) 0.70 (0.17–2.90)
 Widely used 
(> 10,000)
73 (18.9) 18 (24.7) 3.71 (1.56–8.81) 3.31 (0.64–17.25)
 Unknown 123 (31.8) 8 (6.5) 0.79 (0.29–2.12) 0.59 (0.15–2.31)
Specialist indication  < 0.001 0.037  < 0.001
 Yes 295 (76.2) 17 (5.8) Ref Ref Ref
 No 92 (23.8) 24 (26.1) 5.77 (2.94–11.34) 7.28 (1.13–46.97) 5.32 (2.64–10.73)
Drug age (in years) 0.009 0.012 0.010
 ≤ 2 92 (23.8) 11 (12.0) 0.60 (0.27–1.32) 0.49 (0.17–1.36) 0.45 (0.19–1.10)
 3–5 93 (24.0) 6 (6.5) 0.30 (0.12–0.79) 0.32 (0.10–0.97) 0.30 (0.11–0.82)
 6–11 94 (24.3) 4 (4.3) 0.20 (0.06–0.60) 0.15 (0.04–0.51) 0.18 (0.06–0.58)
 > 11 108 (27.9) 20 (18.5) Ref Ref Ref
 DHPC year (con-
tinuous)
387 (100) 41 (10.6) 0.87 (0.82–0.96) 0.003 0.87 (0.80–0.96) 0.003 0.88 (0.81–0.96) 0.003
Issue clinical 0.387
 No 21 (5.4) 1 (4.8) Ref




 No 349 (90.2) 36 (10.3) Ref




 No 316 (81.7) 35 (11.1) Ref
 Yes 71 (18.3) 6 (8.5) 0.74 (0.30–1.84)
Issue other 0.999
 No 373 (96.4) 41 (11.0) Ref
 Yes 14 (3.6) 0 (0.0) 0.00 (−)
Media coverage of DHPCs
A—alimentary tract and metabolism, B—blood and blood forming organs, C—cardiovascular system, J—Anti infectives for systemic use, 
L—anti neoplastic and immunomodulating agents, M—musculo-skeletal system, N—nervous system, other: D—dermatologicals, G—genito 
urinary system and sex hormones, H—systemic hormonal preparations, excl. sex hormones and insulins, R—respiratory system, S—sensory 
organs, V—various
Values in italics indicates a determinant likely to be associated (p < 0.05) with newspaper coverage in the final multivariate regression model
ATC Anatomical Therapeutic Chemical, CI confidence interval, OR odds ratio, ORadj adjusted odds ratio, Ref reference
Table 1  (continued)
DHPCs (%) Covered (%) Univariate p value Full multivariate 
model
p value Final multivariate 
model
p value




 No 365 (94.3) 37 (10.1) Ref
 Yes 22 (5.7) 4 (18.2) 1.97 (0.63–6.13)












Fig. 2  Newspaper articles before and after the direct healthcare pro-
fessional communication (DHPC) was published. The x-axis repre-
sents the index dates of the DHPCs. On the y-axis shown in blue are 
the number of newspaper articles covering the drug safety issue after 
the DHPC has been published and in green the number of newspaper 
articles are shown that covered the drug safety issue before the DHPC 
was published. The dashed line indicates 20 newspaper articles. EE 
ethinylestradiol. Program used: Rstudio
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drug use, specialist indication, clinical issue, shortage issue, 
defect/manufacturing issue, withdrawal and drug use* spe-
cialist indication. The multivariate analysis for social media 
coverage showed that DHPCs concerning drugs without a 
specialist indication and for which the DHPC was published 
because of clinical issues were more likely to be covered 
[ORadj 6.92; 95% CI (1.56–30.64), 5.46; (2.03–14.66) 
(Table 2)]. The sensitivity analysis, in which the social 
media coverage was corrected for posting frequency in two 
reference periods, showed slightly attenuated results, but 
specialist indication [2.31; (1.00–5.40)] and DHPCs for 
clinical issue [4.01; (1.57–10.20)] still were more likely to 
be covered by social media (Table 2 of the ESM).
3.2.1  Secondary Aim
In the 14 days before the DHPC was published, 4162 social 
media postings were retrieved mentioning the drug for which 
the DHPC had been published. These postings covered 119 
(54.1%) of the 220 DHPCs. The median number of post-
ings per covered DHPC was five (IQR 2; 16). Overall, 186 
DHPCs (84.6%) were covered both in the 14 days before 
and 14 days after the DHPC was published. More drugs 
for which DHPCs were published received social media 
posts (30.5%) in the 14 days after the DHPC publication 
than before (2.7%; McNemar’s nominal p < 0.001). In com-
parison, 132 of the drugs mentioned in the 220 DHPCs 
(60.0%) were covered in the 28-day period preceding the 
study period, and 116 DHPCs (52.7%) were covered in the 
reference period during a similar 28-day period 1 year later.
In the 14 days after a DHPC was published, eight drugs 
received more than 100 postings: cyproterone acetate/ethi-
nylestradiol (251 postings after the DHPC on a restriction to 
the indication, new contraindication and new safety informa-
tion on venous thromboembolism and arterial thromboem-
bolism risk), sibutramine (167 postings after the DHPC on 
suspension registration due to cardiovascular risk), rosigli-
tazone (129 postings after the DHPC on suspension registra-
tion due to cardiovascular risk), isotretinoin (125 postings 
after the DHPC on severe skin reaction) and domperidone 
(108 postings after the DHPC on new recommendations to 
minimalise cardiovascular risk) (Fig. 3, Table 1 of the ESM). 
Three of these DHPCs also received more than 100 post-
ings in the 14 days before the DHPCs was published. These 
postings concerned iron-containing products (2332 postings 
after and 2393 before the DHPC on hypersensitivity reac-
tions in intravenous use), levothyroxine (254 postings after 
and 157 before the DHPC on change in packaging leads to 
increased adverse drug events, mostly hyperthyroidism) and 
diclofenac (231 postings after and 143 before the DHPC on 
cardiovascular risk and contraindication). Finally, one drug 
received more than 100 postings only in the 14 days before 
the DHPC was published: ethinylestradiol and norgestimaat 
(128 postings before the DHPC on recall) (Fig. 3, Table 1 
of the ESM).
4  Discussion
This paper provides an overview of 15 years of newspaper 
and 6 years of social media coverage of drug safety issues 
that were communicated through DHPCs. Newspaper arti-
cles covered around one out of ten safety issues published 
in DHPCs. Social media paid attention to around eight out 
of ten drugs for which a DHPC had been published. News-
papers were more likely to cover safety issues concerning 
drugs without a specialist indication as well as older drugs. 
This coverage, however, declined over the years. Social 
media coverage was associated with drugs mentioned in 
published DHPCs reporting on drugs without a specialist 
indication as well as new clinical safety issues.
Coverage of safety issues and drugs in newspapers 
(trend), respectively, social media (significant) for which 
a DHPC had been published, even if discussed at times 
already earlier, increased once the DHPC was published.
The low coverage of DHPCs in newspapers implies that 
only a selective group of safety issues receives attention 
in the traditional media. This may not come as a surprise 
because a Canadian study showed that although 65% of 
newspaper articles are health related, less than 5% were 
related to healthcare treatment/management [20]. This might 
be explained by a study on health news reports, which states: 
“the value of health information relies on whether people 
can use it” [34]. Therefore, one may suggest that for news-
papers, in most cases, reporting drug safety issues is not seen 
as valuable for their readers. This low coverage contrasts 
strongly with the high social media coverage. Postings, how-
ever, were not limited to the specific safety issues communi-
cated through DHPCs, and such postings may be related to 
other health matters as well. Coverage was, however, clearly 
higher (82%) in the period after the DHPC was published 
than in the reference periods (55–60%), or the 14-day period 
immediately preceding the DHPC (54.1%). These data sug-
gest that social media attention for drug safety issues truly 
exceeds newspaper attention. This difference may be caused 
by newspapers weighting the value of reporting, or not, on 
drug safety issues. For example, newspaper editors may 
consider the potential readers’ interest, perceived relevance 
of the safety issue, possible societal impact and concomi-
tant/competing news. Social media, in contrast, is mostly 
unregulated and anyone can post a story. Some drugs gen-
erated constant activity on social media, particularly issues 
regarding the use of diclofenac, iron products and levothy-
roxine. Many safety issues in the newspapers were covered 
both before and after the DHPC was published. This may be 
the result of the time between the identification of a safety 
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Table 2  Determinants of social media coverage in the 14 days after the publishing of a direct healthcare professional communication (DHPC): 
univariate, full multivariate and final multivariate analyses
DHPCs (%) Covered (%) Univariate p value Full multivariate 
model
p value Final multivariate 
model
p value
220 180 (81.8) OR (95% CI) ORadj (95% CI) ORadj (95% CI)
Drug class (ATC 
code)
0.847
 A 20 (9.1) 20 (100.0) Ref
 B 22 (10.0) 18 (81.8) 0 (–)
 C 19 (8.6) 16 (84.2) 0 (–)
 J 18 (8.2) 14 (77.8) 0 (–)
 L 71 (32.3) 59 (83.1) 0 (–)
 M 15 (6.8) 11 (73.3) 0 (–)
 N 21 (9.5) 18 (85.7) 0 (–)
 Other 34 (15.5) 24 (70.5) 0 (–)
Type of molecule 0.516
 Biological 61 (27.7) 49 (80.3) Ref
 Small molecule 157 (71.4) 130 (82.8) 1.18 (0.55–2.51)
 Vaccine 2 (0.9) 1 (50.0) 0.25 (0.01–4.20)
Orphan drug 0.221
 No 190 (86.4) 153 (80.5) Ref
 Yes 30 (13.6) 27 (90.0) 2.18 (0.63–7.56)
Drug use 0.029 0.365
 Low (1 to < 1000) 74 (33.6) 61 (82.4) Ref Ref
 Moderate (1000–
10,000)
38 (17.3) 34 (89.5) 1.81 (0.55–5.99) 1.23 (0.34–4.46)
 Widely used 
(> 10,000)
39 (17.7) 36 (92.3) 2.56 (0.68–9.59) 0.91 (0.16–5.10)
 Unknown 69 (31.4) 49 (71.0) 0.52 (0.24–1.15) 0.51 (0.21–1.24)
Specialist indication 0.012 0.562 0.011
 Yes 172 (78.2) 134 (77.9) Ref Ref Ref
 No 48 (21.8) 46 (95.8) 6.52 (1.51–28.11) 2.02 (0.19–21.81) 6.92 (1.56–30.64)
Drug age (in years) 0.370
 ≤ 2 44 (20.0) 35 (79.5) 1.20 (0.48–2.99)
 3–5 56 (25.5) 49 (87.5) 2.16 (0.83–5.66)
 6–11 48 (21.8) 41 (85.4) 1.81 (0.69–4.77)
 > 11 72 (32.7) 55 (76.4) Ref
DHPC year (continu-
ous)
220 (100) 180 (81.8) 0.92 (0.74–1.15) 0.459
Issue clinical 0.001 0.020 0.001
 No 21 (9.5) 11 (52.4) Ref Ref Ref




 No 190 (86.4) 160 (84.2) Ref Ref




 No 163 (74.1) 140 (85.9) Ref Ref
 Yes 57 (25.9) 40 (70.2) 0.39 (0.19–0.79) 0.61 (0.23–1.64)
Issue other 0.223
 No 215 (97.7) 177 (82.3) Ref
 Yes 5 (2.3) 3 (60.0) 0.32 (0.05–1.99)
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A—alimentary tract and metabolism, B—blood and blood forming organs, C—cardiovascular system, J—anti infectives for systemic use, 
L—anti neoplastic and immunomodulating agents, M—musculo-skeletal system, N—nervous system, other: D—dermatologicals, G—genito 
urinary system and sex hormones, H—systemic hormonal preparations, excl. sex hormones and insulins, R—respiratory system, S—sensory 
organs, V—various
Values in italics indicates a determinant likely to be associated (p < 0.05) with newspaper coverage in the final multivariate regression model
ATC Anatomical Therapeutic Chemical, CI confidence interval, OR odds ratio, ORadj adjusted odds ratio, Ref reference
Table 2  (continued)
DHPCs (%) Covered (%) Univariate p value Full multivariate 
model
p value Final multivariate 
model
p value




 No 208 (94.5) 172 (82.7) Ref Ref
 Yes 12 (5.5) 8 (66.7) 0.42 (0.12–1.47) 0.30 (0.05–1.70)












Fig. 3  Social media postings before and after the direct healthcare 
professional communication (DHPC) was published. The x-axis rep-
resents the index dates of the DHPCs. On the y-axis shown in blue 
are the number of social media postings covering the drug mentioned 
in the DHPC in the 14 days after the DHPC has been published and 
in green the number of social media postings are shown that covered 
the drug mentioned in the DHPC in the 14  days before the DHPC 
was published. The numbers of postings of iron products before and 
after the DHPCs was published were beyond the maximal value of 
the y-axis (before 2393 and after 2332). EE ethinylestradiol. Program 
used: Rstudio
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signal and its confirmation after regulatory review and the 
subsequent decision to issue a DHPC. In this time period, 
the safety issue may have already been derived from sci-
entific publications, marketing authorisation holder press 
releases or regulatory agency websites announcing that they 
are investigating a particular safety signal [1]. Social media 
appeared more reactive, showing more activity for the drug 
in question after a DHPC was published than before.
Our finding that DHPCs related to drugs without a spe-
cialist indication were covered more often seems to be in 
line with earlier studies showing a high newspaper cover-
age of non-specialist drugs, such as cyproterone acetate/
ethinylestradiol (Diane-35) and rofecoxib [Vioxx (selec-
tive serotonin reuptake inhibitor)] [13, 35]. With regard to 
social media, one might also expect more postings by lay-
people on common non-specialist drugs because such drugs 
are more widely used. Drugs already with older marketing 
authorisations were associated with more newspaper cover-
age then recently authorised drugs. The reason for this is 
not clear but it could be that newspaper journalists prefer to 
focus on safety issues regarding well-known drugs and are 
less interested in similar information about relatively new, 
less familiar drugs. Somewhat to our surprise is that safety 
issues were covered less frequently over time by newspapers. 
This finding does not indicate journalists may become more 
averse of drug risks, but could just reflect that the number 
of newspapers is declining [36].
In our study, coverage by newspapers and social media 
are not directly comparable, owing to the different meth-
ods of coverage measured; i.e. discussion of safety issues in 
the newspaper articles respectively mentioning of the drug 
names in social media posts. In addition, the time periods 
were different as well as the reach of newspaper articles and 
individual posts. We noted, however, differences in drugs 
with safety issues that received large interest from news-
papers and social media. Both media covered cyproterone 
acetate/ethinylestradiol and diclofenac, but surprisingly 
sibutramine and rosiglitazone were only covered by social 
media. These products, indicated for obesity and diabetes 
mellitus, respectively, were both withdrawn from the mar-
ket as a result of their cardiovascular risk (Table 2 of the 
ESM). In view of the seriousness of their safety issues with 
both drugs not having a specialist indication, newspapers 
surprisingly did not cover these cases. In contrast, in the 
period before social media were included, rimonabant, also 
indicated for obesity, and celecoxib, a non-steroidal anti-
inflammatory drug, were extensively covered by newspapers. 
For both drugs, most of the coverage preceded the issuing of 
the DHPC reflecting that in these cases the safety issue had 
already been derived from marketing authorisation holders’ 
press releases or scientific papers. In the case of celecoxib 
before the DHPC was published, the marketing authorisation 
holder communicated about its increased cardiovascular risk 
as observed in two separate clinical trials [37, 38]. In the 
month before a DHPC was published regarding psychiatric 
side effects associated with rimonabant, the US Food and 
Drug Administration had announced that they would not 
approve this weight reduction drug because of their concerns 
with this particular safety issue [39]. In addition, just a few 
days before a third DHPC was published for rimonabant, 
the European Medicines Agency announced online its with-
drawal, which is reflected in the coverage in Dutch newspa-
pers that preceded this third DHPC (Fig. 2) [40]. In the case 
of cyproterone acetate/ethinylestradiol 3 weeks before the 
DHPC, the Pharmacovigilance Risk Assessment Commit-
tee finished its assessment and immediately published its 
report [41]. These European Medicines Agency announce-
ments rather than the DHPC seem therefore responsible for 
the newspaper coverage that preceded the publishing of the 
respective DHPCs.
4.1  Implication
Coverage of drug safety issues is not always as balanced as 
one would like it to be [24, 42]. A study examining media 
attention in the USA with regard to next-day drowsiness 
as the result of zolpidem intake showed that media cover-
age was not always complete and therefore sometimes only 
provided a partial view of the message the DHPC intended 
to convey [24]. Our study showed that drug safety issues 
are most likely to be covered when they involve non-spe-
cialist older drugs. As coverage of these drug safety issues 
in the newspapers and the drug names in social media was 
also observed before the DHPC was published, regulators 
could benefit from screening the media immediately prior 
to publishing a DHPC. At this stage, DHPCs are usually 
still fine-tuned between regulatory agencies and marketing 
authorisation holders. Concerns and uncertainties about the 
safety issue as identified in the media could be addressed and 
the message towards healthcare professionals in the DHPCs 
adjusted accordingly.
In The Netherlands, drug safety issues addressed in 
DHPCs are often shared by professional organisations on 
social media. Although these social media postings are 
directed toward healthcare professionals, it should be noted 
that patients use these platforms extensively to share experi-
ences about drugs and use it as a source for medical informa-
tion [43–45]. Although patients are not targeted by DHPCs, 
the information will reach them when it is gleaned by the 
media [46, 47]. When communicating about drug safety 
issues, regulators and professional organisations should keep 
this in mind and possibly provide lay versions of these com-
munications as well.
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4.2  Strengths/Limitations
The present study provided a unique and comprehensive 
review of newspaper and social media coverage of DHPCs 
over 15- and 6-year study periods, respectively. Some limi-
tations should, however, be mentioned. We only looked 
at newspaper and social media coverage, but television or 
radio coverage of a drug may also have been important as 
this could have influenced subsequent newspaper and social 
media coverage [14, 16]. In addition, people could have 
learned from a drug safety issue through other means than 
the DHPC, e.g. they could have been triggered by other 
social media postings and have posted a response or new 
thread on the drug that is not necessarily based on actual 
awareness of the DHPC itself. We did not assess the sever-
ity of safety issues, which may have been a determinant for 
the media to cover a DHPC. All safety issues were, how-
ever, considered of sufficient importance for the regulator 
to issue an urgent safety communication, i.e. a DHPC. We 
did not make statistical adjustments for multiple compari-
sons. Our assessment of determinants is therefore explora-
tive of nature, and can be used as a starting point to focus 
the monitoring of the public’s response to drug safety issues 
by national regulatory agencies. For cerivastatin and doxo-
rubicin, two DHPCs were published within 2 months and 
may have resulted in a double count of newspaper articles 
for these drugs. We discuss the more salient issues using 
an arbitrary cut-off of 20 newspaper articles and 100 social 
media postings covering DHPCs. Other cut-offs could have 
identified safety issues and some newspapers or social 
media posts may have a larger impact, but this is beyond the 
scope of this paper. With regard to social media, the most 
important limitation was that postings were not screened 
for their content. We performed a sensitivity analysis, using 
two reference periods as a correction, with the assumption 
that social media postings in the reference periods should 
not have been affected by the safety issue addressed in the 
DHPCs. This analysis suggested that social media coverage 
was still increased after the DHPC. Finally, we used a short 
observation period for the social media (14 days), assuming 
that posts shortly after a related DHPC had been published 
were more likely associated with the communicated safety 
issue.
5  Conclusions
The present study provides an overview of how often new 
information about drug safety issues communicated through 
DHPCs was covered in newspaper articles and circulates on 
social media during 15 respectively 6-year study periods 
in The Netherlands. Newspapers covered only 10% of the 
safety issues mentioned in DHPCs. Social media covered 
82% of the drugs mentioned in the DHPCs in the period 
shortly after they were published. Overall, DHPCs concern-
ing drugs without a specialist indication were more likely to 
receive coverage by both media types. Newspaper coverage 
was associated with older drugs and coverage became less 
frequent towards the end of our study period.
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